Hare, Stephanie M. http://orcid.org/0000-0002-7350-0351
Adhikari, Bhim M.
Mo, Chen
Chen, Shuo
Wijtenburg, S. Andrea
Seneviratne, Chamindi http://orcid.org/0000-0002-3135-2979
Kane-Gerard, Samuel
Sathyasaikumar, Korrapati V.
Notarangelo, Francesca M.
Schwarcz, Robert
Kelly, Deanna L.
Rowland, Laura M.
Buchanan, Robert W.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (P50-MH103222, P50-MH103222, P50-MH103222, P50-MH103222)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 1 November 2022
Revised: 31 March 2023
Accepted: 6 April 2023
First Online: 28 April 2023
Competing interests
: RS is co-founder of KyNexis AB, which develops novel drugs targeting kynurenine pathway metabolism. RWB performs consultation for Boehringer-Ingelheim and serves on the Data Safety and Monitoring Boards of Roche, Merck and Newron; and on the Advisory Boards of Merck, Acadia, and Neurocrine. DLK is a consultant for Janseen, Alkermes and Sunovion. All other authors declare no competing interests.